Dr. Nastoupil on Challenges Faced With CAR T-Cell Therapy in DLBCL

Video

Loretta J. Nastoupil, MD, discusses challenges faced with CAR T-cell therapy in patients with diffuse large B-cell lymphoma.

Loretta J. Nastoupil, MD, a medical oncologist in the Department of Lymphoma/Myeloma, of the Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses challenges faced with CAR T-cell therapy in patients with diffuse large B-cell lymphoma (DLBCL).

It has been shown that CAR T-cell therapy can potentially cure patients with chemotherapy-refractory DLBCL, although the approach is underutilized, according to Nastoupil. Logistically, the approach is not without challenges, adds Nastoupil. For example, this modality can only be administered at registered treatment centers, which requires a referral from a treating physician in most cases. DLBCL is a disease that progresses quickly; therefore, the time it takes for a patient to receive a referral, be seen at the center, and undergo successful cellular infusion presents a challenge, Nastoupil says. Additionally, identifying patients who should receive CAR T-cell therapy is another area in need of further exploration, according to Nastoupil.

Other novel treatment options have entered the landscape within the past few years that don't require a referral and are also worth considering in this patient population, Nastoupil adds. However, in the next few years, a key focus will be to identify patients for curative therapy and refer them to centers that are administering these cellular therapies. Patients who are suited to more palliative treatments should receive tafasitamab (Monjuvi), polatuzumab (Polivy), and selinexor (Xpovio), Nastoupil notes.

Real-world data or collective expert opinion will be needed to disseminate knowledge that cannot be conveyed through prospective studies, Nastoupil concludes.

Recent Videos
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
© 2024 MJH Life Sciences

All rights reserved.